RO112619B1 - Derivaţi de fluorcitidină, procedeu pentru obţinerea acestora şi compoziţie farmaceutică ce conţine aceşti derivaţi - Google Patents

Derivaţi de fluorcitidină, procedeu pentru obţinerea acestora şi compoziţie farmaceutică ce conţine aceşti derivaţi

Info

Publication number
RO112619B1
RO112619B1 RO93-01706A RO9301706A RO112619B1 RO 112619 B1 RO112619 B1 RO 112619B1 RO 9301706 A RO9301706 A RO 9301706A RO 112619 B1 RO112619 B1 RO 112619B1
Authority
RO
Romania
Prior art keywords
radical
derivatives
pharmaceutical composition
fluorocytidine
integer
Prior art date
Application number
RO93-01706A
Other languages
English (en)
Inventor
Motohiro Arasachi
Hideo Ishitsuka
Isami Kuruma
Masanori Miwa
Chikako Murasaki
Nobuo Shimma
Isao Umeda
Original Assignee
F. Hoffmann - La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RO112619(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag. filed Critical F. Hoffmann - La Roche Ag.
Publication of RO112619B1 publication Critical patent/RO112619B1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Invenţia se referă la derivaţi de fluorocitidină având formula generală structurală I de mai jos:(I)în care radicalul Reste un radical de hidrocarbură saturată sau nesaturată, cu catenă lineară sau ramificată, în care numărul de atomi de carbon în catena lineară cea mai lungă a acestui radical de hidrocarbură este cuprins între 3 şi 7, sau un radical cu formula: -(CH)n-Y, în care n este un număr întreg de la 0 la 4, când Y este un radical ciclohexil, sau n este un număr întreg de la 2 la 4, când Y este un radical alcoxi inferior având de la 1 la 4 atomi de carbon sau un radical fenil, şi radicalul Reste reprezentat de un atom de hidrogen sau un radical uşor hidrolizabil în condiţii fiziologice, precum şi hidraţii sau solvataţii acestor compuşi cu formula generală I. De asemenea, invenţia mai conţine procedeul de preparare a acestor derivaţi, precum şi o compoziţie farmaceutică pe bază de aceşti derivaţi, ca ingrediente active. Aceşti compuşi prezintă activitate antitumorală crescută.
RO93-01706A 1992-12-18 1993-12-15 Derivaţi de fluorcitidină, procedeu pentru obţinerea acestora şi compoziţie farmaceutică ce conţine aceşti derivaţi RO112619B1 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121538 1992-12-18

Publications (1)

Publication Number Publication Date
RO112619B1 true RO112619B1 (ro) 1997-11-28

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
RO93-01706A RO112619B1 (ro) 1992-12-18 1993-12-15 Derivaţi de fluorcitidină, procedeu pentru obţinerea acestora şi compoziţie farmaceutică ce conţine aceşti derivaţi

Country Status (40)

Country Link
US (1) US5472949A (ro)
EP (1) EP0602454B1 (ro)
JP (1) JP2501297B2 (ro)
KR (1) KR100347218B1 (ro)
CN (1) CN1035617C (ro)
AT (1) ATE137244T1 (ro)
AU (1) AU671491B2 (ro)
BG (1) BG61485B1 (ro)
BR (1) BR9305089A (ro)
CA (1) CA2103324C (ro)
CZ (1) CZ284788B6 (ro)
DE (1) DE69302360T2 (ro)
DK (1) DK0602454T3 (ro)
EE (1) EE03086B1 (ro)
ES (1) ES2086856T3 (ro)
FI (1) FI112365B (ro)
GE (1) GEP20074251B (ro)
GR (1) GR3020286T3 (ro)
HR (1) HRP931430B1 (ro)
HU (2) HU218291B (ro)
IL (1) IL108000A0 (ro)
IS (1) IS4108A (ro)
LT (1) LT3115B (ro)
LV (1) LV10625B (ro)
MY (1) MY109282A (ro)
NO (1) NO300066B1 (ro)
NZ (1) NZ250414A (ro)
PH (1) PH30168A (ro)
PL (1) PL174100B1 (ro)
RO (1) RO112619B1 (ro)
RU (2) RU2493162C1 (ro)
SA (1) SA93140409B1 (ro)
SI (1) SI9300648B (ro)
SK (1) SK281403B6 (ro)
SV (1) SV1993000080A (ro)
TW (1) TW372239B (ro)
UA (1) UA39158C2 (ro)
UY (1) UY23697A1 (ro)
YU (1) YU49411B (ro)
ZA (1) ZA939293B (ro)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
OA11659A (en) * 1998-09-25 2004-12-08 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
IL150953A0 (en) * 2000-02-28 2003-02-12 Aventis Pharma Sa A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
WO2001076581A1 (en) * 2000-04-11 2001-10-18 Sayuri Yamada Curcumin compositions
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
BR0306861A (pt) 2002-01-14 2004-11-03 Novartis Ag Combinações que compreendem epotilonas e antimetabólitos
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003274576A1 (en) * 2002-11-15 2004-06-15 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
CA2525973A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
ATE402185T1 (de) * 2003-12-22 2008-08-15 Hoffmann La Roche Verfahren für fluorcytidinderivate
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
AU2006228581A1 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
NZ565654A (en) 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
JP2009501734A (ja) 2005-07-21 2009-01-22 ヌボ・リサーチ・インコーポレイテッド 癌の治療方法
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
BRPI0810067A2 (pt) * 2007-04-20 2014-10-21 Reddys Lab Ltd Dr Processo para a preparação de capecitabina
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es) * 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF CAPECITABINE
WO2010063080A1 (en) * 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
EP2416774B1 (en) 2009-04-06 2015-11-04 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
CN102858791A (zh) * 2009-07-23 2013-01-02 台湾神隆股份有限公司 制备氟胞苷衍生物的方法
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
EP3050882B1 (en) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US8911736B2 (en) 2010-03-12 2014-12-16 Genzyme Corporation Combination therapy for treating breast cancer
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
EP3035966A1 (en) * 2013-08-20 2016-06-29 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
WO2015191563A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin c
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
CN111801339B (zh) * 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
EP3908261A1 (en) 2019-01-11 2021-11-17 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
CN115768778A (zh) 2020-04-21 2023-03-07 配体药物公司 苄氧基磷酸(膦酸)酯化合物
EP4143199B1 (en) 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3189501A1 (en) 2020-08-31 2022-03-03 Emory University 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093B1 (en) 2022-12-05 2025-08-27 a Fine House S.A. Oral suspensions comprising capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Also Published As

Publication number Publication date
NO934671L (no) 1994-06-20
US5472949A (en) 1995-12-05
GEP20074251B (en) 2007-12-10
PL301541A1 (en) 1994-06-27
EP0602454B1 (en) 1996-04-24
FI935616A0 (fi) 1993-12-14
KR100347218B1 (ko) 2003-01-24
RU2135511C1 (ru) 1999-08-27
SV1993000080A (es) 1996-01-26
SI9300648B (sl) 2000-06-30
SI9300648A (en) 1994-09-30
LV10625A (lv) 1995-04-20
KR940014428A (ko) 1994-07-18
HK1005875A1 (en) 1999-01-29
NZ250414A (en) 1995-12-21
NO934671D0 (no) 1993-12-17
YU49411B (sh) 2006-01-16
HU211965A9 (en) 1996-01-29
CN1094056A (zh) 1994-10-26
IS4108A (is) 1994-06-19
UA39158C2 (uk) 2001-06-15
CN1035617C (zh) 1997-08-13
DE69302360D1 (de) 1996-05-30
BR9305089A (pt) 1994-07-05
EP0602454A1 (en) 1994-06-22
JP2501297B2 (ja) 1996-05-29
ES2086856T3 (es) 1996-07-01
DE69302360T2 (de) 1996-10-31
SA93140409B1 (ar) 2004-07-24
SK281403B6 (sk) 2001-03-12
JPH06211891A (ja) 1994-08-02
RU2493162C1 (ru) 2013-09-20
LV10625B (en) 1996-04-20
NO300066B1 (no) 1997-04-01
PH30168A (en) 1997-01-21
HRP931430B1 (en) 1999-08-31
CA2103324A1 (en) 1994-06-19
DK0602454T3 (da) 1996-07-29
LTIP1627A (en) 1994-07-15
HU9303525D0 (en) 1994-04-28
YU77993A (sh) 1996-10-18
ATE137244T1 (de) 1996-05-15
HRP931430A2 (en) 1998-06-30
TW372239B (en) 1999-10-21
UY23697A1 (es) 1994-06-08
AU671491B2 (en) 1996-08-29
EE03086B1 (et) 1998-04-15
LT3115B (en) 1994-12-27
ZA939293B (en) 1994-06-18
GR3020286T3 (en) 1996-09-30
CZ284788B6 (cs) 1999-03-17
BG61485B1 (bg) 1997-09-30
MY109282A (en) 1996-12-31
FI935616L (fi) 1994-06-19
IL108000A0 (en) 1994-04-12
FI112365B (fi) 2003-11-28
HUT65757A (en) 1994-07-28
BG98304A (bg) 1994-01-03
SK144493A3 (en) 1994-10-05
CA2103324C (en) 1997-12-23
HU218291B (en) 2000-07-28
RU2458932C2 (ru) 2012-08-20
AU5069093A (en) 1994-06-30
PL174100B1 (pl) 1998-06-30
CZ273193A3 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
RO112619B1 (ro) Derivaţi de fluorcitidină, procedeu pentru obţinerea acestora şi compoziţie farmaceutică ce conţine aceşti derivaţi
AU6782090A (en) 2-substituted phenyl-2-oxazoline or thiazoline derivatives, process for producing the same and insectides and acaricides containing the same
RO115159B1 (ro) Derivaţi de piperazină şi compoziţii farmaceutice care îi conţin
MY128985A (en) 5'-deoxy-cytidine derivatives
ZA898678B (en) Compositions and compounds
MD422C2 (ro) Derivaţi ai azolului şi compuţi intermediari pentru producerea lor
HUT53648A (en) Process for producing selective adenosine receptors and pharmaceutical compositions comprising same as active ingredient
AU625886B2 (en) New oxazolopyridine derivatives, process for preparing them and pharmaceutical compositions containing them
ZA986337B (en) Pyrazine derivatives their preparation and medicaments containing them
DE60237323D1 (de) Zusammensetzung enthaltend Ferrocen-Derivate und Treibstoff diese enthaltend
SE9701912D0 (sv) Pharmaceutical composition and use thereof
IL83164A (en) Pharmaceutical compositions containing 2,3-dihydro-5-(hetero)aryl-imidazo(2,1-a)isoquinolines,some new such compounds and their preparation
FR2508030B1 (ro)
EA199800767A1 (ru) Производные 1(2h)хинолинкарбоновой кислоты, способ их получения и их применение в синтезе веществ, обладающих антибиотическими свойствами
MY113552A (en) Bicyclic isothiourea derivatives useful in therapy